Webinar: ACR/CHEST ILD Guidelines in Practice| Video: All the Lonely People

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout

  |  

We read the case report by Dr. Diana Girnita and colleagues (“Severe Refractory Gout: What options are left when pegloticase fails?” The Rheumatologist, August 2016) with interest. A case is reported of a subject with 20 years of chronic refractory gout who failed to respond to pegloticase therapy, and the potential roles of anti-drug antibodies or…

Mechanistic, Epidemiologic Clues Suggest Possible Link Between Obesity, Inflammation in Rheumatoid Arthritis

  |  

Obesity has an established systemic inflammatory component. Could that be a trigger for the inflammation seen in rheumatoid arthritis (RA) and other rheumatic diseases? Although there is no direct scientific evidence, both mechanistic and epidemiologic clues do give some intriguing suggestions of a possible link. “At first, we thought that fat was involved only in…

Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

Rheumatoid Arthritis Research Provides New Insights on Risk Factors, Identification Tools, Intervention

  |  

Established wisdom holds that patients with rheumatoid arthritis (RA) will fare better if their disease is diagnosed as early as possible, and treatments with disease-modifying drugs are started before inflammation can do more damage to joints and tissue. Usually, early diagnosis means spotting the clinical signs of disease, but new research tells us more about…

Targeted Therapy for Scleroderma Fibrosis

Sara R. Schoenfeld, MD, & Flavia V. Castelino, MD  |  

Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis

  |  

Abaloparatide for Osteoporosis Abaloparatide is completing Phase III clinical trials for the potential treatment of postmenopausal osteoporosis in women who are at an increased risk of fracture.1 Abaloparatide is a synthetic peptide that engages the parathyroid hormone receptor and has favorable bone building activity. Abaloparatide has completed Phase 3 development for use as a daily…

Rheumatologists on the Move, October 2016

Ann-Marie Lindstrom  |  

Dr. Amanda King Elected President of Caribbean Association for Rheumatology The Caribbean Association for Rheumatology (CAR) elected Amanda King, MBBS(UWI), MRCP(UK), FRCP(Glas.), president during the 7th Annual CAR Scientific Meeting this summer. This year’s CAR meeting concentrated on education for general practitioners, because there are still some islands without a rheumatologist. She is the only rheumatologist…

NYU Langone’s Division of Rheumatology in Manhattan Advances Its Mission to Understand Rheumatic Diseases, Improve Patient Outcomes

  |  

From its beginnings as the Rheumatic Diseases Study Group (RDSG) in the early 1930s, NYU Langone Medical Center’s Division of Rheumatology has been built on a tradition of research and clinical care. Today’s division, with 24 full-time and 76 part-time faculty members, continues to push toward understanding the pathogenesis of rheumatic diseases and interventions to…